Antitumor Activity of Pasireotide (SOM230) Alone and in Combination with Everolimus (RAD001) in DU-145 Human Prostate Cancer Model.

被引：0
|
作者：
Schmid, H. A. [1 ]
Lambertini, C. [1 ]
Nuciforo, P. [1 ]
机构：
[1] Novartis Inst Biol Res, Basel, Switzerland
来源：
ENDOCRINE REVIEWS | 2010年 / 31卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：1
相关论文
共 9 条
  • [1] Antitumor Activity of Pasireotide (SOM230) alone and in Combination with Everolimus (RAD001) in DU-145 Human Prostate Cancer Model
    Schmid, H. A.
    Lambertini, C.
    Nuciforo, P.
    NEUROENDOCRINOLOGY, 2010, 92 (01) : 12 - 12
  • [2] Tumor growth inhibition after Pasireotide (SOM230) in a rat prostate tumor model (DU-145) alone and in combination with Everolimus (RAD001)
    Schmid, Herbert A.
    Paolo, Nuciforo
    ENDOCRINE JOURNAL, 2010, 57 : S589 - S589
  • [3] Inhibitory effect of pasireotide (SOM230) in a rat pancreatic tumor model (CA20948) alone and in combination with everolimus (RAD001)
    Schmid, Herbert
    Jensen, Michael
    CANCER RESEARCH, 2009, 69
  • [4] Phase I Study of Pasireotide (SOM230) in Combination With Everolimus (RAD001) in Patients With Advanced Neuroendocrine Tumors (NET)
    Chan, Jennifer A.
    Ryan, David P.
    Fuchs, Charles S.
    Zhu, Andrew X.
    Abrams, Thomas A.
    Wolpin, Brian M.
    Casey, Carolyn
    Regan, Eileen
    Cavanaugh, Kristen
    Kulke, Matthew H.
    PANCREAS, 2011, 40 (02) : 325 - 325
  • [5] Preclinical evidences suggest new treatment options for endocrine disorders: Pasireotide (SOM230) and Everolimus (RAD001)
    Schmid, H. A.
    ANNALES D ENDOCRINOLOGIE, 2008, 69 (02) : 162 - 163
  • [6] Updated results of a phase I study of pasireotide (SOM230) in combination with everolimus (RAD001) in patients (pts) with advanced neuroendocrine tumors (NET).
    Chan, J. A.
    Ryan, D. P.
    Fuchs, C. S.
    Zhu, A. X.
    Abrams, T. A.
    Wolpin, B. M.
    Malinowski, P.
    Regan, E.
    Kulke, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [7] Antitumor activity of the mTOR pathway inhibitor RAD001 (everolimus) alone or in combination with Temodal®, against U87MG orthotopic glioblastoma tumors in mice.
    Muller, M
    Vaxelaire, J
    Hattenberger, M
    Stauffer, F
    Lane, H
    Maira, M
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9006S - 9006S
  • [8] Hyaluronic Acid Nanohydrogel Loaded With Quercetin Alone or in Combination to a Macrolide Derivative of Rapamycin RAD001 (Everolimus) as a New Treatment for Hormone-Responsive Human Breast Cancer
    Quagliariello, Vincenzo
    Iaffaioli, Rosario Vincenzo
    Armenia, Emilia
    Clemente, Ottavia
    Barbarisi, Manlio
    Nasti, Guglielmo
    Berretta, Massimiliano
    Ottaiano, Alessandro
    Barbarisi, Alfonso
    JOURNAL OF CELLULAR PHYSIOLOGY, 2017, 232 (08) : 2063 - 2074
  • [9] The antiproliferative effect of pasireotide LAR alone and in combination with everolimus (RAD001) in patients with progressive medullary thyroid cancer (MTC): A single-center, open-label, phase II, proof-of-concept study
    Faggiano, A.
    Colao, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
1